The combination heart failure drug sacubitril/valsartan is well-covered under Medicare Part D plans, according to a recent analysis, but patient access to the medication remains limited by steep out-of-pocket costs than can exceed $1,600 annually.
Only half of the world’s countries offer cardiac rehabilitation programs, according to a recent survey, leaving some 18 million heart patients across the globe without access to therapy that could vastly improve their prognosis and quality of life.
Heart patients of a lower socioeconomic status are far more likely to participate in cardiac rehabilitation if they receive financial incentives to attend sessions, according to a study published in the July 1 edition of JACC: Heart Failure.
One in five Americans are able to recognize the symptoms of heart failure, according to a new survey from Abbott—a troublesome finding considering the same research puts the average individual just four degrees of separation from HF.
Researchers at Imperial College London have developed a sew-on heart patch that leverages stem cells to support and repair heart muscle after a heart attack—something that could dramatically lower MI survivors’ risk of future heart failure.